ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression (MOD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02189057
Recruitment Status : Completed
First Posted : July 14, 2014
Last Update Posted : October 22, 2018
Sponsor:
Information provided by (Responsible Party):
Mark Frye, Mayo Clinic

July 8, 2014
July 14, 2014
October 22, 2018
November 2014
October 19, 2018   (Final data collection date for primary outcome measure)
Change in depression as measured by the Quick Inventory of Depressive Symptoms (QIDS-C16) [ Time Frame: baseline, 8 weeks ]
The QIDS-C16 is a 16-item scale that is clinician-rated; it is designed to assess the severity of depressive symptoms. The QIDS-C16 total score ranges from 0-27. Scores ranging from 0 to 10 correspond with no to mild depression, while scores >/= 11 correspond to moderate to severe depression. A negative change indicates improvement in the subject's depression, and a positive change indicates a worsening of the subject's depression.
Baseline to endpoint change in depression [ Time Frame: 8 weeks ]
The primary outcome measure will be baseline to endpoint change in the Quick Inventory of Depressive Symptomatology (QIDS-C16).
Complete list of historical versions of study NCT02189057 on ClinicalTrials.gov Archive Site
  • Number of subjects with improvement of depressive symptoms as shown by 50% reduction in QIDS-C16 score [ Time Frame: 8 weeks ]
    The QIDS-C16 is a 16-item scale that is clinician-rated; it is designed to assess the severity of depressive symptoms. The QIDS-C16 total score ranges from 0-27. Scores ranging from 0 to 10 correspond with no to mild depression, while scores >/= 11 correspond to moderate to severe depression. A negative change indicates improvement in the subject's depression, and a positive change indicates a worsening of the subject's depression.
  • Number of subjects with improvement of depressive symptoms as shown by a score <6 on QIDS-C16 [ Time Frame: 8 weeks ]
    The QIDS-C16 is a 16-item scale that is clinician-rated; it is designed to assess the severity of depressive symptoms. The QIDS-C16 total score ranges from 0-27. Scores ranging from 0 to 10 correspond with no to mild depression, while scores >/= 11 correspond to moderate to severe depression. A negative change indicates improvement in the subject's depression, and a positive change indicates a worsening of the subject's depression.
  • Number of subjects with improvement of depressive symptoms as shown by score of "much" or "very much improved" on Clinical Global Impression - Improvement Scale [ Time Frame: 8 weeks ]
    The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: 1. Very much improved, 2. Much improved, 3. Minimally improved, 4. No change, 5. Minimally worse, 6. Much worse, 7. Very much worse
  • Improvement of depressive symptoms as shown by the Hamilton Rating Scale for Depression (HAMD-17) [ Time Frame: 8 weeks ]
    The HAMD-17 is a 17-item scale that evaluates depressed mood, vegetative and cognitive symptoms of depression, and co-morbid anxiety symptoms. The 17 items are rated on either a 5-point (0-4) or a 3-point (0-2) scale. In general, the 5 point scale items use a rating of 0=absent; 1=doubtful to mild; 2=mild to moderate; 3=moderate to severe; 4=very severe. The 3-point scale items use a rating of 0=absent; 1=probable or mild; 2=definite. The total HAMD-17 score ranges from 0 (not ill) to 52 (severely ill). A negative change indicates improvement in the subject's depression/anxiety symptoms, and a positive change indicates a worsening of the subject's depression/anxiety symptoms.
  • Improvement of depressive symptoms [ Time Frame: 8 weeks ]
    Treatment adherence based on concordance vs. non-concordance of gene test results and clinical intervention.
  • Improvement of depressive symptoms [ Time Frame: 8 weeks ]
    QIDS-C16 response (50% reduction)
  • Improvement of depressive symptoms [ Time Frame: 8 weeks ]
    QIDS-C16 remission (<6)
  • Improvement of depressive symptoms [ Time Frame: 8 weeks ]
    Clinical global impression (CGI) from preceding phase of "much" or "very much improved"
  • Improvement of depressive symptoms [ Time Frame: 8 weeks ]
    Baseline to endpoint change in Hamilton Rating Scale for Depression (HAMD-17)
  • Improvement of depressive symptoms [ Time Frame: 8 weeks ]
    Treatment adherence based on concordance vs. non-concordance of gene test results and clinical intervention.
Not Provided
Not Provided
 
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression
A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management of Depression
The overall goal of this investigator-initiated trial is to evaluate the treatment outcome of depression utilizing platform algorithm products that can allow rapid identification of pharmacokinetic (PK) and/or pharmacodynamic (PD) genomic variation. This new technology may have the potential to optimize treatment selection by improving response, minimizing unfavorable adverse events / side effects and increasing treatment adherence.
Treatment seeking depressed patients (SCID confirmed major depressive disorder or bipolar I/II disorder) to the Mayo Clinic Depression Center will be invited to participate in this study evaluating the Assurex GeneSight® platform; this new technology can rapidly assess PK and PD genetic variation that can potentially impact antidepressant, antipsychotic, and stimulant associated treatment outcomes for depression. This study will recruit treatment seeking patients with major depression with an index episode of moderate symptom severity that has been unresponsive or poorly tolerated to at least one prior antidepressant treatment. This will be an 8-week, double-blind trial where depressed patients are randomized to testing results of GeneSight® (tricolored clinical report) prior to treatment selection (n=138) vs. treatment as usual (tricolored dummy report) (n=138). All testing results will be made available after the 8-week trial.
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Subjects will be randomized to either genotyping intervention or treatment as usual.
Masking: Double (Participant, Investigator)
Masking Description:
Subject and study staff will be blind to randomization.
Primary Purpose: Treatment
  • Depression
  • Mood Disorder
  • Bipolar
  • Other: AssureRx GeneSight genotyping results
  • Other: Treatment as usual
  • Experimental: GeneSight guided treatment
    GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
    Intervention: Other: AssureRx GeneSight genotyping results
  • Active Comparator: Treatment as usual group
    Treatment as usual group will have treatment recommendations based on clinical judgment
    Intervention: Other: Treatment as usual
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
160
276
October 19, 2018
October 19, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 18-65, male or female, any race/ethnicity
  2. Mayo Clinic Depression Center inpatient or outpatient, or an outpatient of Mayo Clinic Rochester and satellite clinics, and outpatients from Mayo Clinic Health System clinics
  3. Ability to provide informed consent
  4. Structured Clinical Interview (SCID) confirmed major depressive episode associated with Major Depressive Disorder, Bipolar I/II disorder, or Schizoaffective Bipolar Disorder
  5. Current index episode of major depression < 2 years duration
  6. Moderate symptom severity defined by HAMD-17 rating scale score ≥ 17 [8]
  7. Current index episode having not been treated with psychotropic medications or inadequately responsive to treatment (IRT). IRT defined as intolerability, adverse event, or inadequate efficacy of current psychotropic medication (at least 4 weeks duration)
  8. Agree to abide by the study protocol and its restrictions and be able to complete all aspects of the study, including all visits and tests
  9. Negative serum or urine pregnancy test (or history of hysterectomy)
  10. Negative urine toxicology test (will only be completed at the request of the treating clinician).

Exclusion Criteria:

  1. Inability to speak English
  2. Inability or lack of willingness to provide informed consent
  3. Axis I or II disorder other than depression (i.e., by clinical assessment) that is the primary reason for treatment
  4. Psychotropic medication change (including dosage) between screening & baseline visit with exception of no more than 8mg of Ativan within a 24-hour period.
  5. Patients who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for any significant current substance use disorder other than nicotine or caffeine. Must have at least early, partial or full, remission X 3 months
  6. Clinically diagnosed cannabis use disorder, or SCID confirmed cannabis abuse or dependence.
  7. Current clinical diagnosis delirium, dementia, other cognitive disorders, or non-mood psychotic disorder (i.e., schizophrenia, delusional disorder)
  8. Index episode symptoms of hallucinations or delusions
  9. Serious suicidal risk and/or in need of immediate hospitalization as judged by the investigator
  10. History of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic for 6 months
  11. Significant unstable medical condition
  12. Hepatic insufficiency (2.5 X upper limit of normal (ULN) for Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ), past liver transplant recipient, and/or clinical diagnosis of cirrhosis of the liver
  13. Malignancy (except basal cell carcinoma) and/or chemotherapy within 1 year prior to screening; malignancy more than 1 year prior to screening must have been local and without metastasis and/or recurrence, and if treated with chemotherapy, without nervous system complications
  14. Participation in another clinical trial within 30 days of the screening visit
  15. Anticipated inability to attend scheduled study visits
  16. Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol
  17. Known cytochrome (CYP) & serotonin transporter genomic testing results within 5 years
  18. A score of ≥15 on the Young Mania Rating Scale (YMRS)
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02189057
13-007981
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Mark Frye, Mayo Clinic
Mayo Clinic
Not Provided
Principal Investigator: Mark Frye, MD Mayo Clinic
Mayo Clinic
October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP